These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Determination of circulating IgG subclasses against lipoarabinomannan in the leprosy spectrum and reactions. Beuria MK, Mohanty KK, Katoch K, Sengupta U. Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):422-8. PubMed ID: 10700917 [Abstract] [Full Text] [Related]
7. Dose-dependent thalidomide induced bradycardia in young erythema nodosum leprosum patient. Thangaraju P, Venkatesan S, Sivashanmugam E, Showkath Ali MK. Indian J Pharmacol; 2019 Dec; 51(1):72-74. PubMed ID: 31031470 [Abstract] [Full Text] [Related]
8. Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: A five-year retrospective analysis from a leprosy referral centre in India. Upputuri B, Pallapati MS, Tarwater P, Srikantam A. PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008678. PubMed ID: 33035210 [Abstract] [Full Text] [Related]
9. Daily multidrug therapy for leprosy; results of a fourteen-year experience. de Carsalade GY, Wallach D, Spindler E, Pennec J, Cottenot F, Flageul B. Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752 [Abstract] [Full Text] [Related]
10. Differential immunoglobulin and complement levels in leprosy prior to development of reversal reaction and erythema nodosum leprosum. Amorim FM, Nobre ML, Nascimento LS, Miranda AM, Monteiro GRG, Freire-Neto FP, Queiroz MDCP, Queiroz JW, Duthie MS, Costa MR, Reed SG, Johnson WD, Dupnik KM, Jeronimo SMB. PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007089. PubMed ID: 30689631 [Abstract] [Full Text] [Related]
11. Tumor necrosis factor: status in reactions in leprosy before and after treatment. Bhattacharya SN, Chattopadhaya D, Saha K. Int J Dermatol; 1993 Jun; 32(6):436-9. PubMed ID: 8320025 [Abstract] [Full Text] [Related]
12. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide. Feuth M, Brandsma JW, Faber WR, Bhattarai B, Feuth T, Anderson AM. Lepr Rev; 2008 Sep; 79(3):254-69. PubMed ID: 19009975 [Abstract] [Full Text] [Related]
14. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN. J Infect Dis; 1993 Aug; 168(2):408-14. PubMed ID: 8335978 [Abstract] [Full Text] [Related]
17. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. J Exp Med; 1992 Jun 01; 175(6):1729-37. PubMed ID: 1588290 [Abstract] [Full Text] [Related]
18. Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day. Putinatti MS, Lastória JC, Padovani CR. An Bras Dermatol; 2014 Jun 01; 89(2):266-72. PubMed ID: 24770503 [Abstract] [Full Text] [Related]